- Home
- IBRX vs KYN Comparison
IBRX vs KYN Comparison
Compare IBRX & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- KYN
- Stock Information
- Founded
- IBRX 2014
- KYN 2004
- Country
- IBRX United States
- KYN United States
- Employees
- IBRX N/A
- KYN N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- KYN Finance/Investors Services
- Sector
- IBRX Health Care
- KYN Finance
- Exchange
- IBRX Nasdaq
- KYN Nasdaq
- Market Cap
- IBRX 2.4B
- KYN 2.0B
- IPO Year
- IBRX N/A
- KYN N/A
- Fundamental
- Price
- IBRX $2.87
- KYN $12.38
- Analyst Decision
- IBRX Strong Buy
- KYN
- Analyst Count
- IBRX 5
- KYN 0
- Target Price
- IBRX $11.40
- KYN N/A
- AVG Volume (30 Days)
- IBRX 10.1M
- KYN 561.5K
- Earning Date
- IBRX 08-11-2025
- KYN 01-01-0001
- Dividend Yield
- IBRX N/A
- KYN 8.99%
- EPS Growth
- IBRX N/A
- KYN N/A
- EPS
- IBRX N/A
- KYN 0.71
- Revenue
- IBRX $31,222,000.00
- KYN N/A
- Revenue This Year
- IBRX $567.98
- KYN N/A
- Revenue Next Year
- IBRX $160.56
- KYN N/A
- P/E Ratio
- IBRX N/A
- KYN $13.79
- Revenue Growth
- IBRX 10238.41
- KYN N/A
- 52 Week Low
- IBRX $1.83
- KYN $7.84
- 52 Week High
- IBRX $7.63
- KYN $9.88
- Technical
- Relative Strength Index (RSI)
- IBRX 49.40
- KYN 54.93
- Support Level
- IBRX $2.77
- KYN $12.26
- Resistance Level
- IBRX $3.24
- KYN $12.60
- Average True Range (ATR)
- IBRX 0.23
- KYN 0.17
- MACD
- IBRX -0.03
- KYN -0.01
- Stochastic Oscillator
- IBRX 19.74
- KYN 50.00
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About KYN Kayne Anderson Energy Infrastructure Fund Inc.
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.